Research graph
References from Implementation and First Results of the Czech Nationwide Prostate Cancer Screening Pilot Program. Local targets link to admitted publications; unresolved targets remain external evidence.
Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
2021 · External reference
Unresolved reference
2024 · External reference
Early detection of prostate cancer in 2020 and beyond: facts and recommendations for the European Union and the European Commission
10.1016/j.eururo.2020.12.010 · 2021 · External reference
European study of prostate cancer screening - 23-year follow-up
10.1056/nejmoa2503223 · 2025 · External reference
Opportunistic testing versus organized prostate-specific antigen screening: outcome after 18 years in the Göteborg randomized population-based prostate cancer screening trial
10.1016/j.eururo.2014.12.006 · 2015 · External reference
Risk-stratified approach to implementing population-based prostate cancer screening in five pilot sites in the European Union: a protocol for the PRAISE-U project
10.1016/j.euros.2024.09.003 · 2024 · External reference
Systematic review on the cost effectiveness of prostate cancer screening in Europe
10.1016/j.eururo.2024.04.036 · 2024 · External reference
Health policy for prostate cancer early detection in the European Union and the impact of opportunistic screening: PRAISE-U consortium
10.3390/jpm14010084 · 2024 · External reference
How to follow the new EU Council recommendation and improve prostate cancer early detection: the Prostaforum 2022 declaration
10.1016/j.euros.2023.05.011 · 2023 · External reference
Prostate cancer early detection in the European Union and UK
10.1016/j.eururo.2024.07.019 · 2025 · External reference
Unresolved reference
2024 · External reference
Prostate cancer screening-when to start and how to screen?
10.21037/tau.2017.12.25 · 2018 · External reference
A European model for an organised risk-stratified early detection programme for prostate cancer
10.1016/j.euo.2021.06.006 · 2021 · External reference
MRI-targeted or standard biopsy in prostate cancer screening
10.1056/nejmoa2100852 · 2021 · External reference
Integration of data and information systems into the health data strategy
10.2196/70066 · 2025 · External reference
10.2139/ssrn.5361655
10.2139/ssrn.5361655 · External reference
Prostate cancer screening decisions: which aspects do men value most? An interview study with men invited to a population-based program
10.1177/15579883251344563 · 2025 · External reference
Population-based organised prostate cancer testing: results from the first invitation of 50-year-old men
10.1016/j.eururo.2023.11.013 · 2024 · External reference
Prostate cancer screening with PSA, kallikrein panel, and MRI: the ProScreen randomized trial
10.1001/jama.2024.3841 · 2024 · External reference
Age-specific reference ranges for PSA in the detection of prostate cancer
1997 · External reference
Prostate cancer screening with PSA and MRI followed by targeted biopsy only
10.1056/nejmoa2209454 · 2022 · External reference
Prostate cancer screening with PSA: ten years’ experience of population based early prostate cancer detection programme in Lithuania
10.3390/jcm9123826 · 2020 · External reference
Swedish regional population-based organised prostate cancer testing: why, what and how?
10.2340/sju.v60.43809 · 2025 · External reference
Magnetic resonance imaging–based biopsy strategies in prostate cancer screening: a systematic review
10.1016/j.eururo.2025.05.038 · 2025 · External reference
MRI capacity assessment for prostate cancer screening in five sites of Europe
10.1016/j.ejrad.2025.112235 · 2025 · External reference
Associations between socioeconomic factors and PSA testing in a population-based organised testing programme and routine healthcare: a register-based study of 50-year-old men
2024 · External reference
Organized prostate cancer screening program: a proposal from the Italian Society of Urology (SIU)
10.23736/s2724-6051.24.06117-2 · 2024 · External reference
